Overview
Current Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
In the News
View All News
Recent Publications
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.
Journal Article Clin Cancer Res · June 3, 2025 PURPOSE: Comprehensive molecular profiling was used to define the genomic and immune landscapes of leiomyosarcomas (LMS) by anatomic subtypes, which have not been completely characterized. EXPERIMENTAL DESIGN: A total of 1,115 LMS samples, categorized into ... Full text Link to item CiteGenomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.
Conference Oncologist · December 6, 2024 BACKGROUND: Malignant phyllodes tumors (MPT) are rare fibroepithelial breast cancers with no known effective systemic therapy; metastatic progression portends a dismal prognosis. We sought to describe the genomic landscape of MPTs through genomic profiling ... Full text Link to item CiteProspective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy-Impact on clinical outcome.
Journal Article Int J Cancer · December 1, 2024 The purpose of this study was to determine if dual-energy CT (DECT) vital iodine tumor burden (ViTB), a direct assessment of tumor vascularity, allows reliable response assessment in patients with GIST compared to established CT criteria such as RECIST1.1 ... Full text Link to item CiteRecent Grants
A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology, Inc. · 2025 - 2030A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour,
Clinical TrialPrincipal Investigator · Awarded by SynOx Therapeutics Ltd · 2025 - 2030A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic
Clinical TrialPrincipal Investigator · Awarded by Intensity Therapeutics, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
2000
M.D.